Skip to main content

OptimizeRx Named to Financial Times ―The Americas’ Fastest-Growing Companies List for the Second Consecutive Year

Written by Customer Service on . Posted in Public Companies.

ROCHESTER, Mich. , April 13, 2021 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians, and patients, has received the ranking of #277 by the Financial Times (FT) list of The Americas’ Fastest Growing Companies 2021. This recognition is presented by the FT and Statista Inc., the world-leading statistics portal and industry ranking provider.

The FT Americas’ Fastest Growing Companies list ranks companies with the strongest compounded annual revenue growth between 2016 and 2019. OptimizeRx grew more than 46% during that period, showing its strongest growth to date in 2020 with full year revenue up 76% year-over-year. Out of the millions of active companies in North and South America, only the top 500 firms are named to the list.

“We are thrilled to be part of the FT Americas’ Fastest Growing Companies ranking, and proud to see our team’s efforts and continuous drive to innovate being recognized for the second year in a row by one of the world’s most widely read and respected business publications,” said William Febbo, CEO of OptimizeRx. “Our platform enhancements over the past year included two critical point-of-care solutions: the integration of AI-powered real-world evidence, and the launch of TelaRep™ – a digital solution that gives prescribers a direct line of communication to the right pharma contact when they need it.

“We believe both patients and providers deserve access to actionable and accurate information about prescription medications. As such, we will continue working on solutions and partnerships to improve drug affordability, access, and adherence. OptmizeRx’s offerings are transformational to physician-patient engagement and define the new modicum of streamlined communications in an increasingly digital-first world. Additionally, we have only just started to touch on the many possible ways of assisting the healthcare industry overcome customer engagement challenges. Looking ahead, we look forward to making operational progress through the remainder of the year and expect to continue seeing record growth,” concluded Mr. Febbo.

About the Financial Times
The Financial Times (FT) is one of the world’s leading business news organizations, recognized internationally for its authority, integrity, and accuracy. The FT has a paying readership of more than a million worldwide, three-quarters of which are digital subscriptions. FT is part of Nikkei Inc., which provides a broad range of information, news, and services for the global business community. For more information, visit www.ft.com. 

About OptimizeRx
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians, and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. 

Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words ‘estimate,’ ‘possible’ and ‘seeking’ and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

OptimizeRx Contact 
Doug Baker, CFO
Tel (248) 651-6568 (x807)
dbaker@optimizerx.com 

Media Relations Contact 
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070 
malejandra@optimizerx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.